Eyed Pharma

EyeD Pharma is a Belgian clinical-stage biotechnology company transforming ophthalmic treatment through innovative sustained-release polymeric micro-implants. Founded in 2012 by Prof. Jean-Marie Rakic, head of ophthalmology at the University Hospital of Liège, alongside a consortium of ophthalmologists and entrepreneurs, EyeD addresses one of medicine's most persistent challenges: poor patient compliance with daily eye drop therapy. Over 1.1 billion people globally suffer from vision loss due to treatable eye diseases such as glaucoma and dry eye, yet many remain untreated or undertreated because frequent instillation of eye drops is burdensome, prone to error, and often causes systemic side effects. EyeD's technology delivers medication directly into the eye through intraocular implants that release drugs in a controlled, sustained manner—some for two years or longer—eliminating the compliance burden and reducing side effects to near-zero levels. The company's pipeline includes several promising candidates: TimoD, a non-biodegradable implant delivering timolol for glaucoma (directly competing with AbbVie's Durysta but with twice the duration and enhanced tolerability); HydraD for dry eye disease; BimatoD for posterior segment conditions such as diabetic macular edema; and InflammaD for inflammatory eye conditions. Each candidate leverages EyeD's proprietary sustained-release platform, reducing development risk and accelerating the path to patients. The company operates a vertically integrated manufacturing facility—UniD Manufacturing, a CDMO (contract development and manufacturing organization) launched in spring 2022—enabling tight control over production, quality, and supply chain, an advantage rare among early-stage biotech firms. EyeD's significance extends beyond product innovation: the company exemplifies how deep-tech biotech can flourish in regions outside traditional pharma hubs. With 100+ employees (primarily in Liège) and a team averaging 18 years of pharmaceutical expertise, EyeD combines academic rigor with commercial ambition. The €45 million funding round in December 2021 (the largest in Wallonia and third-largest in Belgium) underscores investor confidence in both the technology and the company's execution. By advancing these micro-implants toward commercialization, EyeD has the potential to restore vision and quality of life to millions of patients who would otherwise experience progressive blindness from untreated ocular disease. Keywords: ophthalmology, sustained-release, micro-implants, glaucoma, dry eye, clinical-stage biotech, drug delivery, patient compliance, Belgium, deep tech, intraocular therapeutics, ophthalmic innovation, pharmaceutical development, CDMO.